The Role of PARP Inhibition in Prostate Cancer:

e-Learning Now Available

The range of therapeutic options in prostate cancer is expanding, including strategies for PARP inhibition. The aim of this e-learning course is to provide an understanding of the mechanism of action of PARP inhibitors; the prevalence of DNA damage repair (DDR) mutations in advanced prostate cancer, as well as approaches for somatic and germline testing to identify patients with these mutations; and the recent and ongoing clinical trial data on PARP inhibition in advanced prostate cancer. Watch this video from Dr. Neal D. Shore and download the educational slides to learn more. Follow the link below to start your e-learning journey today.

This course has been developed by the following expert faculty:

  • Dr. Neal D. Shore, Carolina Urologic Research Center (Myrtle Beach, South Carolina, USA)
  • Prof. Andrew J. Armstrong, Duke University School of Medicine (Durham, North Carolina, USA)
  • Prof. Emmanuel S. Antonarakis, Johns Hopkins Medicine (Baltimore, Maryland, USA)
Take the e-learning
Download educational slides as PDF
Download educational slides as PPTX
Share feedback

This course has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for 1 European CME Credit. The EACCME® accreditation system is mutually recognised by the AMA and Royal College of Physicians and Surgeons of Canada.

The views expressed in this video are that of the expert and do not necessarily represent the views of the expert’s academic institution, employer, organisation, or other group or individual. AstraZeneca has provided a sponsorship grant towards this independent educational programme.